Navigation Links
PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
Date:4/12/2012

security requirement."

Dr. Fuerst's presentation also highlighted the important technical milestones that PharmAthene achieved for its SparVax™ program during 2011. These include completing technology transfer of the manufacturing process and cGMP manufacturing of the final drug product at full commercial scale.  SparVax™ also demonstrated 36 months of final drug product stability, a particularly noteworthy achievement, as stability has historically been a stumbling block for other rPA vaccine programs.  PharmAthene also increased rPA yield six-fold at the bulk drug substance stage, which is highly significant in terms of being able to fill government stockpile requirements.

PharmAthene's rPA anthrax vaccine program has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority.

About SparVax™ 

SparVax™ is a novel second generation anthrax vaccine being developed to protect against inhalation anthrax, the most lethal form of anthrax infection in humans. The vaccine contains highly purified recombinant protective antigen (rPA) and has been shown to stimulate protection against anthrax by eliciting a specific immune response to one of the primary proteins excreted by the Bacillus anthracis organism. Unlike the first generation anthrax vaccine and other rPA-based anthrax vaccines in development, SparVax™ is produced using E. coli, which enables a much more robust and scalable manufacturing process.  In addition, SparVax™ is capable of being produced at greater than 150 million rPA vaccine equivalent doses per year (at 50 mcg per dose) using a single 1,500-liter fermentor. The unique manufacturing process also mitigates the detrimental effect of proteases. SparVax™ is expected to undergo additional Phase II clinic
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
4. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
5. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
6. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
7. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
8. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
9. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
10. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
11. PharmAthene Completes $6.5 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application and ... analyzes the global market on the basis of ... details such as the key drivers, current trends ... Browse 81 Market Data Tables and 29 Figures ... “1,6-Hexanediol Market by Application and by Geography - ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The Asia-Pacific ... concerned market in Asia-Pacific with analysis and forecast of ... and is expected to reach $51,362.6 million by 2018, ... , Browse through the TOC of the Asia-Pacific hardware ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/18/2014)... 18, 2014 The Asian Electronic Medical Record ... Asian with analysis and forecast of revenue. The electronic medical ... to $2,328.0 million by 2018, at a CAGR of 9.4% ... the Asian Electronic Medical Record (EMR) market, to get an ... glimpse of the segmentation of the market in the same ...
(Date:10/18/2014)... to a new market research report “Hydraulic Fracturing Market ... Forecasts up till 2017”, hydraulic fracturing market will grow ... expected to increase from $40 billion in 2012 to ... same period. North America is expected to lead the ... horse power supplied by the year 2011. , Make ...
Breaking Biology Technology:1,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4
... (Nasdaq: AMLN ) issued the following statement ... Eastbourne Capital Management, L.L.C., made public earlier today:"After significant ... unable to achieve a settlement with Eastbourne and Carl ... shareholders. Of course, we continue to remain open to ...
... ATLANTA, May 20 Germany will present itself ... locations at this year,s BIO,International Convention. Under the ... will provide invaluable insight into the,latest research results ... The,German research landscape and the regulatory framework conditions ...
... N.C., May 20 Asymchem Laboratories, Inc., a leading ... Products to the pharmaceutical industry, with sites in ... the recent addition of Dr. Chris Huber as ... the table over 15 years experience in the ...
Cached Biology Technology:Amylin Responds to Eastbourne Letter 2Amylin Responds to Eastbourne Letter 3Amylin Responds to Eastbourne Letter 4BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine 2Dr. Chris Huber Joins Asymchem Laboratories Inc. as Director of Chemical Development 2
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
(Date:10/15/2014)... risk from strains of influenza virus increases with the ... become complacent that the most substantial threats have been ... pandemics arise when a new virus strain – against ... spreads in the human population. There have been five ... of which – the 1918 Spanish Flu – cost ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... photovoltaic (PV) cells world-wide produced a peak amount of electricity ... located in Europe. Similarly to previous years, this shows the ... new solar systems were installed. By the end of 2009, ... installed) was 16 GW, which is about 70% of the ...
... A surface molecule on bacteria that instructs bone cells ... bone disease, says a scientist speaking at the Society for ... from bacteria could be a way of treating painful bone ... by Meticillin-resistant Staphylococcus aureus (MRSA). Bone disease, ...
... 1. A Low-carb Diet Based on Animal Protein May ... low-carbohydrate diet produces weight loss and improves some cardiovascular ... may depend on the type of protein and fat ... a low-carbohydrate diet for 26 and 20 years respectively. ...
Cached Biology News:Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3Interrupting death messages to treat bone disease 2Embargoed news from Annals of Internal Medicine 2
... transient, cytoplasmic expression of an N-terminal FLAG® ... or selection marker from bicistronic mRNA. ... and MCS2 for transcription of a single ... is useful for protein-protein interaction studies, multi-subunit ...
...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: